AI-guided pathology analysis can help predict immunotherapy response in rare cancers

Researchers from The University of Texas MD Anderson Cancer Center demonstrated that an artificial quality (AI)-based investigation of tumor biopsies tin foretell responses to immunotherapy successful a survey of patients with uncommon cancers, published successful the Journal for ImmunoTherapy of Cancer.